Insilico Medicine, an AI-driven biotech company, has announced its AI-designed COVID-19 drug is entering Phase I clinical trials. Promising to deliver lasting results against all variants, this could become the first viable alternative to Paxlovid.
To stay on top of such cutting-edge advancements in AI, look here first.
Insilico's breakthrough medicine, ISM3312
- Generated using Artificial Intelligence, ISM3312 may offer the superior solution to the constraints of current oral medication, Paxlovid.
- Insilico’s new drug could address the limitations of Paxlovid, including unpleasant side effects and drug resistance due to constant COVID mutation.
- Preclinical studies reveal the drug’s potential in reducing the viral load in lung tissue and mitigating lung inflammation.
Development powered by AI
- Identified via AI-driven platform PandaOmics, the drug effectively targets crucial proteins in the coronavirus.
- Using Chemistry42, a generative chemistry platform, Insilico generated new molecules built to suppress this protein, creating ISM3312.
- Given the success, the company patented ISM3312, which is currently undergoing Phase I Clinical trials, with results expected by end 2023.
The Implications
- Dr. Harvey Castro, an emergency medicine physician, encourages doctors to remain cautious but also recognizes the promise of AI-generated drugs like ISM3312.
- With the trials in progress, the medical community is closely monitoring it as it could redefine the treatment course for COVID and other similar viruses.
- Insilico's venture exhibits AI's potential in accelerating effective drug discovery, prompting the need for consistent tracking of AI's transformation of healthcare and other fields.
P.S. If you like this kind of analysis, I compile a free newsletter that tracks the most relevant news and research in AI. Professionals from Google, Meta, and Insilico Medicine are already reading it.
[link] [comments]